

# Index

## A

- Acanthocheilonema viteae*, 107
- Adaptive immune system
  - regulatory B-cells, 112
  - regulatory T-cells, 111–112
- Aeroallergens, 102
- AhR agonists, 168
- AhR-mediated immune regulation, 182
- Airway and skin biopsies, 6
- Airway eosinophilia, 105
- Airway hyperreactivity, 36
- Airway hyper-responsiveness, 80, 103
- Airway inflammation, 104
- Akaike's information, 54
- Alarmins, 3
- ALEX study, 53, 55
- Allergens
  - bacterial (*see* Bacterial allergens)
  - definition, 27
- Allergen-specific IgE, 108
  - production, 105
  - responses, 211
- Allergic (exogenous) asthma, 27, 28
- Allergic airway diseases, 29–33
- Allergic airway inflammation, 105, 107
- Allergic airway inflammation/atopic dermatitis (AD), 104
- Allergic asthma, 177, 178
- Allergy
  - characterization, 27
  - and *H. pylori* (*see* *Helicobacter pylori*)
  - immune dysfunction, 12–14
  - microbiome protects (*see* Microbiome protects)
  - vs. parasite mediated protection (*see* Parasite mediated protection)
- Allergy exacerbation
  - antigens, 2
  - bacterial wall components, 2
  - epithelial cells and macrophages, 3
  - hygiene hypothesis, 4
  - ILC2s, 3
  - immunoglobulin (Ig) E/type-2 responses, 2
  - inflammation conditions, 3
  - microbiota, 3, 4
  - molecular mimicry, 3
  - neutrophils, 3
  - parasites, 4
  - Th2 cells, 3
  - transcription factors, 3
- Allergy protection, 5, 6
- Allergy-protective effect, 52
- Alpha-gal syndrome, 155
- Anaphylaxis, 180
- Animal fodder, 54
- Animals' skin-draining lymph nodes, 37
- Anisakis simplex* (As-MIF), 106
- Anti-eosinophilic therapy, 214
- Antigen presenting cells (APC), 14, 36
- Anti-IgE mAb (omalizumab), 214, 219
- Anti-IL-5 (mepolizumab), 222
- Anti-inflammatory drugs, 210
- Anti-inflammatory reactions, 70
- Anti-P6 IgE, 39
- Anti-SE IgE, 37
- Apathogenic strain, 85
- Artemin, 179
- Arthropods/reptils, 156

- Aryl hydrocarbon receptor (AhR)  
 AD, 179, 180  
 agonists, 168  
 AhRR/ARNT dimer, 170  
 allergic asthma, 177, 178  
 bHLH motif, 168  
 canonical AhR pathway, 169  
 carbon ring systems, 169  
 DRE and XRE, 169  
 exogenous and endogenous ligands, 171, 172  
 FA, 180, 181  
 host-environment interfaces, 182  
 multiple cell types  
   DCs, T helper cells, eosinophils and mast cells, 174–176  
   tissue barrier cells, 176, 177  
 multitasking effector, 174–181  
 PAS, 169  
 plasticity, 172–174  
 pleiotropic immune regulator, 168  
 signal amplification, 170  
 SWI/SNF chromatin-remodeling, 170  
 TCDD, 170  
 xenobiotic metabolism, 169
- Aryl hydrocarbon receptor repressor (AhRR), 170
- Ascaris-sIgE, 102
- Asthma  
 allergic (exogenous) asthma, 27, 28  
 allergic airway diseases, 29  
 and atopy, 52  
 and bacterial diversity, 59  
 bacterial infection and allergic response, 35  
 bacterial infection and colonization, 29  
 bacterial triggers, 19, 20  
 bronchial, 35, 37, 39  
 definition, 210  
 description, 19  
 development, 69  
 diagnosis, 34  
 and dust, 29  
 exacerbations, 34, 39  
 farm effect, 53  
 heterogeneous disease, 19  
 idiopathic/intrinsic, 27, 28  
 induction and exacerbation, 29, 38  
 intrinsic, 37  
 and microbial diversity, 57, 59  
 microbial triggers and mechanisms, 17, 19  
 molecular patterns, 211  
 murine allergic asthma model, 35, 36  
 Murine asthma models, 58  
 non-allergic (endogenous) asthma, 27, 28  
 onset and exacerbations, 30  
 paediatric, 70  
 pathogenesis, 33, 37  
 pneumococci and incidence, 40  
 prevalence, 57, 69  
 protection, 28, 29, 84  
 risk, 29  
 risk factors, 59  
 suppression, 28  
 symptoms, 39  
 therapy refractory, 36  
 treatment, 210  
 valid biomarkers, 19  
 viral triggers, 20
- Asthma endotypes  
 CD25, 224  
 GATA-3, 225  
 IgE, 214–219  
 IL-4 and IL-13, 219  
 IL-5, 221–223  
 molecular targets, 215–218, 228  
 non-Th2 biologic approaches (*see* Non-Th2 biologic approaches)  
 OX40L, 225  
 pathological features, 210  
 Th2 phenotypes, 213, 214  
 TSLP, 223  
 type 2 biomarkers, 212, 213
- Asthma-related studies, 77
- Asthmatic epithelium exhibits matrix, 210
- Atopic asthma, 55
- Atopic dermatitis (AD)  
 allergens, 16  
 and allergic asthma, 22  
 antiquity, 16  
 characterization, 16  
 colonization and infection, 16  
 exacerbations, 16  
 fungi, 18, 19  
 health and economic burden, 16  
 microbial triggers and mechanisms, 16, 17  
 polyetiologic pathophysiology, 16  
*Staphylococci*, 17–18  
 type 2 dominated inflammation, 22  
 viral infections, 18
- Atopic march, 179
- Atopy/allergic diseases, 77
- Atrophic disorders, 70
- Atypical bacterial pathogens  
*Chlamydia pneumoniae*, 34–35  
*Chlamydia trachomatis*, 33, 34  
*Mycoplasma pneumoniae*, 35–36

## Autoallergy

- description, 20
- immune dysfunction, 12–14
- microbial triggers, 20–22
- T<sub>H</sub>2-biased immune system, 14
- vicious cycle, 14

## Autoimmunity

- bacterial triggers, 15
- immune dysfunction, 12–14
- pathogenesis, 14, 15
- pathomechanisms, 15
- T<sub>H</sub>2-biased immune system, 14
- viral triggers, 16

**B**

Bacillus Calmette-Guérin (BCG), 28

## Bacterial allergens

- allergic airway diseases, 30–33
- allergic deviation, 30
- asthma (*see* Asthma)
- atypical bacterial pathogens, 33–36
- bacterial diversity, 29
- CF, 28
- colonization and allergic diseases, 29
- commensal microflora, 28
- fibroblast growth factors, 29
- human respiratory tract
  - Haemophilus influenzae*, 38–39
  - Moraxella catarrhalis*, 41
  - Pseudomonas aeruginosa*, 41–42
  - Staphylococcus aureus*, 36–38
  - Staphylococcus epidermidis*, 38
  - Streptococcus pneumoniae*, 39–40
  - Streptococcus pyogenes*, 40–41
- and hypersensitivity reactions, 27
- IgE antibodies, 29
- initiation and exacerbations of Th2 immune responses, 30–33
- lung inflammation, 29
- mast cells and basophils, 29
- mechanisms, 29, 30
- mycobacteria, 28
- not related to respiratory tract
  - Borrelia burgdorferi*, 42
  - Staphylococcus saprophyticus*, 42, 43
- respiratory pathogens, 29
- Th1–Th2 immune balance, 28
- vascular endothelial growth factors, 29

Bacterial ribosomes (16s rRNA), 56

## Bacterial triggers

- in asthma, 19, 20
- autoimmunity, 15

Bacterial virulence factors/host's polymorphisms, 72

Basic leucine zipper AFT-like 3 (BATF-3)-dependent DCs, 82

Basic-loop-helix transcription factors (bHLH), 168

Basophils, 108, 221

## B cell

IgE<sup>+</sup> memory, 130–133

Benralizumab, 223

Beta-naphthoflavone (BNF), 170

Bioinformatic analysis, 172

## Biomarkers

- pharmacodynamic, 220
- and Th2 phenotypes, 213, 214
- type 2, 212

Bland-Altman plot, 61

*Borrelia burgdorferi*, 42

Brodalumab, 227

Bronchial asthma, 35, 37, 39

Bronchial hyperresponsiveness, 36, 226

Bronchoalveolar lavage (BAL), 33–36, 38, 41

Bronchodilators, 210

**C**

CagA<sup>+</sup> strains, 82

*Campylobacter jejuni* (*C. Jejuni*), 15

CARDS toxin, 36

CD25, 224

## CD4 T cells

- allergen exposure, 123
- cellular damage and death, 123
- DAMPs, 123, 124
- DCs (*see* Dendritic cells (DCs))
- direct interaction, 124
- epithelial cytokines, 123
- GM-CSF, 123
- heterogeneity of memory
  - asthma model, 128
  - CCR7 and CD62L expression, 128
  - contraction phase, 127
  - follicular helper (T<sub>fh</sub>) cells, 128, 129
  - intense research, 127
  - lung-resident, 128
  - mechanism, 128
  - selection of cells, 127
  - stem cell T memory cells, 129
  - TCR-peptide:MHCII interaction, 128
  - Th2 immunity, 129, 130
  - timing, 128
  - Trm cells, 129
  - oxidative stress/damage, 124

- CD4 T cells (*cont.*)  
 principal function of epithelial barriers, 124  
 skin barrier, 124  
 TSLP, 123  
 type 2 immunity, 123
- Cellular immune response, 34
- Cellular mechanisms, 101
- Cellular memory, 126
- Cellular player, 4, 5
- Chemokines, 210
- Chlamydia pneumoniae*, 34–35
- Chlamydia trachomatis*, 33, 34
- Chronic disease progression, 6
- Chronically exposed farm workers, 54
- Chronic-obstructive pulmonary disease, 54
- Coagulase-negative *Staphylococci* (CoNS), 38, 42
- Colonization, *see* Gastrointestinal tract (GT);  
 Immune programming
- Commensal microflora, 28
- Community-acquired respiratory distress  
 syndrome toxin, 36
- Corticosteroid-refractory severe asthma, 226
- Coxsackie virus B4 (CVB4), 16
- Coxsackie viruses, 18, 22
- CXCR2 receptor, 227
- Cysteine-rich membrane protein (CrpA), 34
- Cystic fibrosis (CF), 28, 41, 42
- Cytokine milieu, 127
- Cytokines, 210
- Cytosolic phospholipase A2 (cPLA2), 173
- D**
- Daclizumab, 224
- Damage-associated molecular patterns  
 (DAMPs), 106, 123, 124
- Dendritic cells (DCs), 73, 109, 110  
 aberrant and excessive exposure, 124  
 activation, 123  
 activation and T cell priming, 123  
 behaviour, 124  
 direct interaction of antigens, 124  
 IL-12, 125  
 IL-6, 124  
 MHC II, 124  
 OX40L, 123  
 to secondary lymph nodes, 122
- Desel exhaust particle (DEP)-polycyclic  
 aromatic hydrocarbons (PAH), 178
- Dose-response relationship, gene expression, 54
- Duodenal ulcers, 72
- Dupilumab, 221
- Dysbalanced microbiome, 228
- Dysbiotic microbial communities, 154
- E**
- Endothelial cells, 210
- Endotoxin various, 55
- Endotoxins, 52, 59, 60
- Endotypes  
 asthma (*see* Asthma endotypes)  
 definitions, 211
- Enokizumab, 227
- Environmental microbiota to mucosal  
 microbiomes, 60–62
- Environmental sensor, 182
- Eosinophilia, 221, 222, 227
- Eosinophilic type-2-high asthma, 222
- Eosinophils, 107, 108, 176, 221, 222
- Epithelial cells, 106
- Epithelial cytokines, 123
- Epstein-Barr virus (EBV), 16
- Estrogen receptor (ER), 172
- Ethiopian immigrants, 102
- European farm children studies, 53
- Experimental autoimmune encephalomyelitis  
 (EAE), 175
- Extracellular polysaccharides (EPS), 58, 59
- Extracellular vesicles (EVs), 37
- F**
- Farm effect, 52
- Farming studies  
 endotoxin, 59–60  
 fungi, 58–59  
 good and bad farming, 53–55  
 Gram-negative bacteria, 59–60  
 and hygiene hypothesis, 52, 53
- Farm-related exposures, 52
- FcepsilonRI, 108
- Fibroblast growth factors, 29
- Fibroblasts, 22
- Fibronectin-binding protein (FBP), 37, 38
- Filarial parasites, 104
- Food allergy (FA), 180, 181  
 activation, memory responses, 133–135  
 CD4 T Cell, 123–125  
 clinical manifestations, 122  
 foodstuff, 122  
 IgE (*see* IgE)

- memory (*see* Memory)
- operating principle, 122
- structural cells and innate cells, 122
- 6-Formylindolo [3,2-b] carbazole (FICZ), 171
- Foxp3
  - CD4<sup>+</sup> intraepithelial cells, 149
  - CTLA-4 expression, 150
  - DCs, 150
  - food allergens, 149
  - Gata3 expression, 151
  - IL-2, 150
  - IL-33, 151
  - intestinal homeostasis, 149
  - IRF4, 150
  - iTreg differentiation, 149
  - musculin, 150
  - Nlrp3, 150
  - pro-allergic immune bias, 152
  - ROR( $\gamma$ t), 151
  - self-antigen recognition, 152
  - STAT3-deficiency, 151
  - TCR, 149
  - transcription factors, 150
  - Tregs, 149
  - type 2 immune responses, 149
  - WASP, 152
- Fraction of exhaled nitric oxide (FeNO), 212, 213
- Fungi, 18, 19, 58, 59

## G

- GABRIELA study, 59, 61, 62
- $\gamma$ -Glutamyltranspeptidase (gGT), 74
- Gastric carcinoma, 72
- Gastrointestinal tract (GT), 191, 192, 219
- GATA-3, 225
- Gel-based techniques, 56
- Gene expression of receptors, 54, 55
- Generic markers, microbial exposure, 55, 56
- Germ-free (GF), 70, 194
- Glutamic acid decarboxylase (GAD-65), 16
- GM-CSF, 81, 123
- Goblet cell metaplasia, 80
- Golimumab, 226
- Good and bad farming, 53–55
- G-protein coupled receptors (GPRs), 195
- Gram-negative bacteria, 52, 59, 60
- Gram-negative  $\epsilon$ -proteobacterium, 70
- Gram-positive bacteria, 37, 39
- Guillain-Barré syndrome (GBS), 15
- Gut microbiome, 63
- Gut microbiota, 70, 197, 198
- Gut-lung axis postulates, 63

## H

- Haemophilus influenzae*, 38–39
- Hair follicles, 155
- Heat shock protein (HSP 60), 34
- Helicobacter neutrophil activating protein* (HP-NAP), 80
- Helicobacter pylori* (*H. pylori*)
  - allergy prevalence, 75–77
  - animal studies, 80–83
  - antibiotic treatment, 83
  - apathogenic strain, 85
  - and asthma, 78, 79
  - characteristic feature, 83
  - chronic colonization and constant inflammation, 72
  - chronic inflammatory and auto-inflammatory disorders, 83
  - epidemiological and experimental data, 83
  - Gram-negative  $\epsilon$ -proteobacterium, 70
  - human gastro-intestinal microbiome, 72
  - human studies, 77–80
  - vs.* immune response, 72–75
  - immunomodulating properties, 83
  - infection, 70, 72
  - infection in adults, 70, 71
  - infection in children, 70, 71
  - person-to-person transmission, 70
  - prevalence, 72
  - semi-mature DCs, 84
- Helminth* infection systems, 123
- Helminth infections, 103
- Helminth-derived modulators, 101
- Helminthic immunomodulator (ES-62), 108
- Herpes simplex virus, 18
- Herpetic stromal keratitis (HSK), 16
- Heterogeneous and versatile cell type, 107
- Heterogeneous disease, 19
- High-affinity receptor Fc $\epsilon$ RI, 211
- Hippocrates, 19
- Histamine, 211
- Hookworm infection, 109
- Hookworms/whipworms, 102
- Host's immune response, 105
- House dust mite (HDM) allergy, 100, 102, 104
- H. polygyrus* excretory secretory products (HES), 111
- huMAb OX40L, 225
- Human anti-TSLP monoclonal IgG2I, 223
- Human gastro-intestinal microbiome, 72
- Human microbiome project, 192
- Human respiratory tract
  - Haemophilus influenzae*, 38–39
  - Moraxella catarrhalis*, 41

Human respiratory tract (*cont.*)

- Pseudomonas aeruginosa*, 41–42
- Staphylococcus aureus*, 36–38
- Staphylococcus epidermidis*, 38
- Streptococcus pneumoniae*, 39–40
- Streptococcus pyogenes*, 40–41

Human rhinovirus (HRV), 20

Humoral memory, 126

Hygiene hypothesis, 70

- and farming studies, 52, 53

Hyper-IgE syndrome, 151

Hypersensitivity reactions, 27

**I**

ICS/LABA treatment, 221, 222

Idiopathic/intrinsic asthma, 27, 28

IgE antibodies, 29

IgE<sup>+</sup> B cells, 131IgE<sup>+</sup> memory B cell, 130–133IgE<sup>+</sup> PC compartment, 134

IgE-mediated allergy, 221

IgE-reactive auto-allergens, 20, 21

IL-2 signalling, 128

IL-4 and IL-13

- blocked, 220
- with chronic asthma, 220
- dupilumab, 221
- FeNO levels, 220
- ICS/LABA treatment, 221, 222
- IgE and blood eosinophil measurements, 220
- IMA-638, 220
- LAVOLTA studies, 220
- lebrikizumab study, 220
- lung function, 220
- molecules targeting, 220
- periostin levels, 220
- pharmacodynamic biomarkers, 220
- pitracinra, 220
- polymorphisms, 221
- tralokinumab (anti-IL-13), 220

IL-4 receptor, 82

IL-4R $\alpha$ , 213

IL-5

- anti-IL-5 (mepolizumab), 222
- basophils, 221
- benralizumab, 223
- computed tomographic imaging, 222
- eosinophilia, 221, 222
- eosinophilic type-2-high asthma, 222
- eosinophils, 221, 222
- mepolizumab, 222, 223
- reslizumab, 223

IL-10 production, 102

IL-17, 227

Immune dysfunction

- allergy, 12–14
- autoallergy, 12–14
- autoimmunity, 12–14
- severe allergy, 12–14

Immune memory in food allergy, 126–127

Immune programming

- anaerobic luminal environment, 193
- breastfeeding, 193
- cesarean section, 193
- GF, 194
- intestinal microbiota, 193
- microbiota composition, 194
- neutralizing antibody content, 193
- operational taxonomic unit analyses, 193
- skin and environmental microbes, 193
- TLRs, 193

Immune response vs. *Helicobacter pylori*

- allergic and chronic autoimmune diseases, 72
- animal studies, 73
- asymptomatic carriers, 72
- bacterial virulence factors or host's polymorphisms, 72
- DCs, 73–75
- gastric malignancies, 72
- IL-10 levels, 73
- regulatory T cell, 73
- T cells, 72, 73
- TGF- $\beta$ , 73

Immunoblots, 34

Immunoglobulin E (IgE), 214

Immunological diseases, 199, 200

Immunomodulatory protease inhibitor, 107

Indole-3-aldehyde (IAld), 171

Indole-3-carbinol (I3C), 172

Indoxyl sulfate (IS), 172

Induced Treg (iTreg) cells, 213

Industrialized farms, 54

Infiltrating leukocytes, 210

Inflammatory disorders, 57

Infliximab, 226

Influenza virus (IFV), 20

Inhaled corticosteroids (ICSs), 213

Innate immune system

- basophils, 108
- DAMPs/alarmins, 106
- DCs, 109–110
- eosinophils, 107–108
- epithelial cells, 106
- ILCs, 109
- larvae damage, 106

- macrophages, 107
- mast cells, 108–109
- neutrophils, 107–108
- parasite releases immunomodulatory molecules, 106
- Innate lymphoid cells (ILCs), 3, 109, 176
- Innate lymphoid cells type 2 (ILC2s), 151
- Innate lymphoid cells 3 (ILC3), 196
- Internal transcribed spacer (ITS), 56
- Intestinal epithelial cells (IECs)
  - glycoproteins, 195
  - gut microbes and adaptive immune cells, 196, 197
  - innate immune cells, 195, 196
  - and mucosal immune cells, 194
  - QS signals, 195
  - SCFAs, 195
  - secretory antimicrobial proteins, 195
- Intraepithelial lymphocytes (IELs), 172
- Intrinsic asthma, 37
- ISAAC studies, 76

## K

- 90-kDa heat shock protein (HSP90), 169
- Keratinocytes, 22, 174, 179
- Kynurenines, 179

## L

- Lactobacillus rhamnosus*, 228
- LAVOLTA studies, 220
- Lebrikizumab, 220, 221
- Lectin binding protein (LBP), 34
- Linear and non-linear dimensionality reduction techniques, 58
- Lipid mediators, 210
- Lipopeptides, 53
- Lipopolysaccharide (LPS), 15, 34
- Lipopolysaccharides, 52, 53
- Litomosoides sigmodontis* (*L. sigmodontis*), 104
- Local and systemic immune system, 196
- Long-acting  $\beta$ -agonists (LABAs), 219
- Low-density lipoprotein (LDL), 171
- Lung inflammation, 29, 80

## M

- Macroparasites, 99
- Major histocompatibility complex (MHC) II, 36
- Major outer membrane protein (MOMP), 34
- Malassezia furfur*, 179
- Malassezia* species, 18, 19

- Manganese superoxide dismutase (MnSOD), 20
- Mast cells (MCs), 108, 176, 210, 211
- Maternal immune system, 102
- Memory
  - CD4 T cells, 127–130
  - cellular, 126
  - compartment, 126
  - humoral, 126
  - IgE<sup>+</sup> memory B cell, 130–133
  - immune, 126–127
  - immunological, 125
  - long-lived PCs, 126
  - long-term memory, 125
  - PCs, 125
  - population of cells, 126
  - responses, 133–135
  - serological, 126
- Memory responses
  - IgE-generating, 133
- Mepolizumab, 222–224
- Mesenteric lymph nodes (MLNs), 74, 81, 84
- Methicillin-Resistant *Staphylococcus aureus* (MRSA), 18
- 3-Methyl-colantrene (3-MC), 170
- Microbes
  - allergic airway inflammation and hypersensitivity pneumonitis, 147
  - allergic disorders, 146
  - body sites, 146
  - chronic inflammatory disorders, 146
  - cytokines, 146
  - eosinophils, 149
  - epidemiology, 153, 154
  - germfree/antibiotic treated mice, 147
  - innate and adaptive immune system, 146
  - intestinal parasite infections, 148
  - lymphoid tissues, 148
  - massive antibiotic treatment, 146
  - mouse model, 148
  - SCFA, 147
  - subcutaneous allergen immune therapy, 149
  - tolerance mechanisms, 146
  - Tregs, 146
  - tTregs and iTregs, 149
  - type 2 immune disorders, 147
  - ulcerative colitis, 148
  - vertebrates and non-vertebrates, 146
- Microbial associated molecular pattern (MAMPS), 195
- Microbial cell wall components, 53
- Microbial cultivation techniques, 211
- Microbial diversity
  - and asthma, 57

Microbial diversity (*cont.*)  
 and hot spots, 57–58  
 in throat and nasal swabs, 63  
 Microbial DNA, 56, 57  
 Microbial dysbiosis, 228  
 Microbial exposure  
 generic markers, 55, 56  
 hot spots, 57–58  
 microbial diversity, 57–58  
 Microbial triggers  
 autoallergy (*see* Autoallergy)  
 autoimmunity (*see* Autoimmunity)  
 severe allergy (*see* Severe allergy)  
 Microbial virulence/host factors, 62–63  
 Microbiome, 227  
 Microbiome complements, 58  
 Microbiome protects  
 endotoxin, 59–60  
 environmental changes, 64  
 environmental microbiota to mucosal  
 microbiomes, 60–62  
 farming studies, 52, 53  
 fungi, 58–59  
 Gram-negative bacteria, 59–60  
 gut microbiome, 63  
 hygiene hypothesis, 52, 53  
 microbial DNA, 56, 57  
 microbial exposure (*see* Microbial  
 exposure)  
 microbial virulence/host factors, 62–63  
 mutual adaptation/maladaptation, 64  
 revolution, 64  
 Microbiota, 7  
 Microbiota modulation strategies, 199  
 Microorganisms, 56  
 Mitogen activated protein kinases (MAPKs), 173  
 Molecular mimicry, 14, 20  
*Moraxella catarrhalis*, 41  
 Mucosa-associated lymphoid tissue (MALT)  
 lymphoma, 72  
 Mucosal microbiomes, 60–62  
 Mucosal/skin compartments, 122  
 Mucous gland hyperplasia, 210  
 Multiple sclerosis, 14  
 Multisensitized atopy, 154  
 Murine allergic asthma model, 35, 36  
 Murine allergy models, 103  
 Murine asthma models, 58  
 Mycobacteria, 28  
 Mycobacterial organism, 28  
*Mycobacterium tuberculosis*, 28  
*Mycoplasma pneumoniae*, 35–36

**N**

N-(3-Oxododecanoyl)-L-homoserine lactone  
 (OdDHL), 42  
 Nasal microbiome, 62  
 Nasal swabs, 62  
 Natural killer T (NKT), 197  
 Neonatal-infected animals, 80  
 Neutrophilic inflammation, 226  
 Neutrophils, 107, 108, 227  
*Nippostrongylus brasiliensis*, 104  
 Non-allergic (endogenous) asthma, 27, 28  
 Non-atopic and viral asthma, 228  
 Non-intestinal barrier sites, 154–156  
 Non-metric multidimensional scaling  
 (NMDS), 58  
 Non-Th2 biologic approaches  
 definition, 226  
 dysbalanced microbiome, 228  
 neutrophils, 227–228  
 RSV, 228  
 Th9, 226, 227  
 TNF- $\alpha$ , 226  
 Nuclear export signal (NES), 169  
 Nuclear localisation signal (NLS), 169  
 Nucleotide sequence, 56

**O**

Operational taxonomic units (OTUs), 61  
 Oral tolerance, 154  
 OVA/alum-induced allergic airway  
 inflammation, 106  
 OVA-alum sensitization, 103  
 OVA-induced asthma, 81  
 OX40L, 225

**P**

Palivizumab, 228  
 Paracelsus' rule, 55  
 Parasite mediated protection  
 adaptive immune system, 110–112  
 anti-allergic and anti-inflammatory effects, 100  
 epidemiology, 101–103  
 HDM allergy, 100  
 helminth infection, 100  
 helminths, 99, 100  
 innate immune system, 105–110  
 leukocytes and structural cells, 105  
 lifecycle, 99  
 preventive and therapeutic effects, 105, 106  
 pro-allergic potential, 100



- in rodent models, 103–105
  - type 2 immune responses, 100
  - type 2 response, 100
- Parasite releases immunomodulatory molecules, 106
- Parasitic immunomodulators, 113
- PARSIFAL study, 53, 54, 56, 58, 63
- PASTURE birth cohort, 63
- Pattern recognition receptors (PRRs), 106, 195
- Peripheral blood mononuclear cells (PBMCs), 34, 35, 40, 128, 178
- Peroxisome proliferator-activated receptor (PPARs), 176
- Pharmacological treatment strategies, 211
- Pitakinra, 220
- Plasma cells (PCs), 125
- Plasmacytoid DCs (pDCs), 81
- Pollen exposure, 52
- Polyclonal IgE levels, 108
- Polymerase chain reaction—single strand conformation polymorphism (PCR-SSCP), 56–58
- Polymorphic outer membrane protein (POMP), 34
- Poria cocos* bark (PCB), 181
- Positive transcription elongation factor (P-TEFb complex), 169
- Principal components analysis (PCA), 58
- Principal coordinate analysis (PCoA), 58
- Pro-allergic microbiome, 156
- Pro-inflammatory mediators, 37
- Proteasome system, 173
- Protein from *A. suum* 1 (PAS-1), 111
- Pseudomonas aeruginosa*, 41–42
  
- Q**
- Quorum sensing (QS), 195
  
- R**
- Regulatory B-cells, 102, 112
- Regulatory T-cells, 73, 80, 82, 102, 104, 109, 111, 112
- Reslizumab, 223
- Respiratory syncytial virus (RSV), 20, 228
- Respiratory tract express PPRs, 106
- Respiratory viruses, 28
- Rheumatoid arthritis, 7
- Rodent models
  - parasite mediated protection vs. allergy
  - allergic airway inflammation/AD, 104
  - artificial/xeno infection, 103
  - conditional knock-outs/adoptive transfer studies, 103
  - disadvantages, 103
  - filarial parasites, 104
  - grass pollen allergy, 105
  - helminth-based prevention/therapy, 103
  - helminthic immunomodulators, 105
  - immunomodulatory mechanisms, 103
  - natural infection, 103
  - prevent allergic inflammation, 105
  - regulatory T-cells, 104
  - respiratory tract, 104
  - Schistosoma* infection, 103–104
  
- S**
- Safe strain, 85
- Schistosoma* infection, 103
- Schistosomal egg antigen (SEA), 109
- Schistosome infection, 101, 102
- Scutellaria baicalensis*, 181
- Secretory immunoglobulin A (sIgA), 195
- Serological memory, 126
- Severe allergy
  - AD, 16–18
  - asthma, 19–20
  - immune dysfunction, 12–14
  - T<sub>H</sub>2-biased immune system, 14
- Short chain fatty acids (SCFA), 113, 147, 193
- Short-lived mediators, 211
- Signalling lymphocyte activation molecule (SLAM) associated protein (SAP) deficiency, 130
- Skin cells, 22
- Skin-draining lymph nodes, 104
- Sm22.6 and Sm29, 111
- Smooth muscle cells, 210
- Soil-transmitted nematodes, 104
- SpID, 38
- Staphylococcal enterotoxins A to U (SEA to SEU), 36
- Staphylococci, 17–18
- Staphylococcus aureus* (*S. aureus*), 6, 16–18, 36–38
- Staphylococcus enterotoxins (SE), 18
- Staphylococcus epidermidis* (*S. epidermidis*), 17, 38
- Staphylococcus saprophyticus*, 42, 43
- Staphylococcus* species, 3
- Stem cell T memory cells, 129

- Streptococcal pyrogenic exotoxins (SPEs), 40  
 Streptococcal superantigens, 40  
*Streptococcus pneumoniae*, 39–40  
*Streptococcus pyogenes*, 40–41  
 Structural cells in airways, 210  
 Superantigens, 36  
 Suppressor of cytokine signaling protein 2 (SOCS-2), 174  
 Systemic corticosteroid-dependent patients, 222
- T**
- T-cell receptor (TCR), 36  
 T cells, 6, 7  
 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), 168  
 TGF- $\beta$  receptor II, 73  
 T<sub>H</sub>2-biased immune system, 14  
   autoallergy, 14  
   autoimmunity, 14  
   severe allergy, 14  
 Th2 cytokines  
   IL-4 and IL-13, 219–221  
   IL-5, 221  
 T helper (Th) responses, 34  
 T helper 17 (Th17) cells, 213  
 Th2 humoral immunity (IgE)  
   and IgG, 129  
   and mediate plasmablast proliferation, 129  
   biology and food allergy, 125  
   cytoplasmic tail, 127  
   memory, 122  
   parasites and poisons, 122  
 Th2 immune responses  
   initiation and exacerbations, 30–33  
 Th2 immunity, 123  
 T<sub>H</sub>2-like response, 70  
 Th2 phenotypes  
   and biomarkers, 213, 214  
 Th2 sensitization, 123, 129  
 T<sub>H</sub>1/regulatory phase, 104  
 Th1–Th2 immune balance, 28  
 Th9, 226, 227  
 T-helper type 2, 27, 28, 35–43  
 Thioredoxin, 20  
 Thymic stromal lymphopoietin (TSLP), 3, 123, 223, 224  
 Tissue damage, 14  
 TLR5, 54  
 TNF- $\alpha$ , 226  
*Tnfrsf3*, 153  
 Toll-like receptors (TLRs), 53, 106, 193  
 Toxic molecules, 108  
 Toxic shock syndrome toxin-1 (TSST-1), 36  
 Toxin theory, 156  
 Tralokinumab (anti-IL-13), 220  
 Transmembrane activator and CAML interactor (TACI), 132  
*Trichuris suis* ova (TSO), 113  
 TSLP-dependent eosinophilic esophagitis, 155  
 Type 2 biomarkers, 212  
 Type 2 cytokine production, 105  
 Type 2 cytokines, 108  
 Type 2 dominated inflammation, 22  
 Type 2 immunity, 123  
 Type 2 immunopathology, 112  
 Type 2 inflammation, 27, 105  
 Type 3 innate lymphoid cells (ILC3), 176  
 Type I immediate hypersensitivity allergic reactions, 211  
 Type-I diabetes (T1D), 16
- U**
- Ubiquitin, 173  
 Unfavourable farm-related exposures, 54
- V**
- Vaccinia virus, 18  
 Vacuolating cytotoxin A (VacA), 74  
 Vascular endothelial growth factors, 29  
 Viral exacerbations, 6  
 Viral-induced asthma, 228  
 Viral triggers  
   in asthma, 20  
   autoimmunity, 16
- W**
- Whipworm, 103  
 Wiskott-Aldrich syndrome protein (WASP), 152  
 World health organization, 199  
 World Health Survey (WHS), 75